Characteristics of anti-CD20 antibodies in vitro.
| Antibody name . | Type . | ADCC . | CDC . | Direct effects . | Reference . |
|---|---|---|---|---|---|
| Abbreviations: ADCC, antibody-dependent cell–mediated cytotoxicity; CDC, complement-dependent cytotoxicity | |||||
| Rituximab | Chimeric IgG1 | ++ | ++ | + | Cragg et al9 |
| Ocrelizumab | Humanized IgG1 | +++ | +/– | + | Vugmeyster et al7 |
| PRO131921 | Engineered ocrelizumab | ++++ | ++ | + | |
| Veltuzumab | Humanized IgG1 | ++ | ++ | + | Stein et al39 |
| Ofatumumab | Human IgG1 | ++ | ++++ | + | Hagenbeek et al4 |
| AME-133 | Humanized IgG1 | ++++ | ++ | ++ | Weiner et al8 |
| GA-101 | Humanized IgG1 | +++++ | – | ++++ | Umana et al10 |
| Antibody name . | Type . | ADCC . | CDC . | Direct effects . | Reference . |
|---|---|---|---|---|---|
| Abbreviations: ADCC, antibody-dependent cell–mediated cytotoxicity; CDC, complement-dependent cytotoxicity | |||||
| Rituximab | Chimeric IgG1 | ++ | ++ | + | Cragg et al9 |
| Ocrelizumab | Humanized IgG1 | +++ | +/– | + | Vugmeyster et al7 |
| PRO131921 | Engineered ocrelizumab | ++++ | ++ | + | |
| Veltuzumab | Humanized IgG1 | ++ | ++ | + | Stein et al39 |
| Ofatumumab | Human IgG1 | ++ | ++++ | + | Hagenbeek et al4 |
| AME-133 | Humanized IgG1 | ++++ | ++ | ++ | Weiner et al8 |
| GA-101 | Humanized IgG1 | +++++ | – | ++++ | Umana et al10 |